Gyon Technologies Capital Management LP Raises Position in CTI BioPharma Corp.
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
About 56% of CTi Biopharma's investor base is looking to short. The analysis of current outlook of investing in CTi Biopharma Corp suggests that many traders are alarmed regarding CTi Biopharma's prospects. The current market sentiment, together with CTi Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use CTi Biopharma Corp stock news signals to limit their universe of possible portfolio assets.
CTi |
Gyon Technologies Capital Management LP raised its position in CTI BioPharma Corp. by 138.2 percent during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 192,831 shares of the biopharmaceutical companys stock after acquiring an additional 111,891 shares during the quarter. Gyon Technologies
Read at thelincolnianonline.com
 |
CTi Biopharma Fundamental Analysis
We analyze CTi Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
CTi Biopharma is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
CTi Biopharma Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CTi Biopharma stock to make a market-neutral strategy. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics with similar companies.
Peers
CTi Biopharma Related Equities
| MCRB | Seres Therapeutics | 6.98 | ||||
| MDGL | Madrigal Pharmaceuticals | 5.12 | ||||
| TGTX | TG Therapeutics | 4.04 | ||||
| CDTX | Cidara Therapeutics | 3.15 | ||||
| VKTX | Viking Therapeutics | 1.83 | ||||
| PLX | Protalix Biotherapeutics | 1.75 | ||||
| RIGL | Rigel Pharmaceuticals | 0.70 | ||||
| FBIO | Fortress Biotech | 1.69 | ||||
| IBRX | Immunitybio | 1.87 | ||||
| CRVS | Corvus Pharmaceuticals | 1.96 | ||||
| IMMP | Immutep | 4.25 | ||||
| XFOR | X4 Pharmaceuticals | 4.69 | ||||
| VSTM | Verastem | 5.63 | ||||
| PDSB | PDS Biotechnology | 5.71 | ||||
| ELEV | Elevation Oncology | 7.94 | ||||
| RVPH | Reviva Pharmaceuticals | 10.67 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |